• 1
    Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337:17331745.MEDLINE
  • 2
    Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333:16571661.MEDLINE
  • 3
    Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991; 88:84958499.MEDLINE
  • 4
    Lai CL, Chien R-N, Leung NWY, Chang T-T, Guan R, Tai D-I, Ng K-Y, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339:6168.MEDLINE
  • 5
    Leung NWY, Lai CL, Liaw YF, Chang TT, Guan R, Tai DI, Ng KY, et al. Lamivudine (100 mg od) for 1 year significantly improves necro-inflammatory activity and reduces progression in fibrosis stage: results of a placebo-controlled multicentre study in Asia of lamivudine for chronic hepatitis B infection [Abstract]. Hepatology 1997; 26(Suppl 4):357A.
  • 6
    Tanikawa K, Hayashi N, Ichida F, Lino S, Kumada H, Ogawa N, Okida K, et al. A placebo-controlled phase III study of lamivudine in Japanese patients with chronic hepatitis B infection [Abstract]. Hepatology 1997; 26(Suppl 4):259A.
  • 7
    Main J, Brow JL, Howells C, Galassini R, Crossey M, Karayiannis P, Georgiou P, et al. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J Viral Hepat 1996; 3:211215.MEDLINE
  • 8
    Gilson RJ, Chopra K, Murray-Lyon IM, Newell AM, Nelson MR, Tedder RS, Toole JJ, et al. A placebo-controlled phase I/II study of adefovir dipivoxil (bis-POM PMEA) in patients with chronic hepatitis B infection [Abstract]. Hepatology 1996; 24(Suppl 4):281A.
  • 9
    Deeks SG, Collier A, Lalezari J, Pavia A, Rodrigue D, Drew WL, Toole J, et al. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J Infect Dis 1997; 176:15171523.MEDLINE
  • 10
    Jeffers L, Heathcote E, Wright T, Carithers R, di Bisceglie A, Perillo R, Rustgi V, et al. A phase II dose-ranging, placebo-controlled trial of adefovir dipivoxil for the treatment of chronic hepatitis B virus infection [Abstract]. Antiviral Res 1998; 37:A197.
  • 11
    Bloomer J, Chan R, Sherman M, Ingraham P, DeHertogh D. A preliminary study of lobucavir for chronic hepatitis B [Abstract]. Hepatology 1997; 26(Suppl 4):428A.
  • 12
    Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997; 41:14441448.MEDLINE
  • 13
    Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123126.MEDLINE
  • 14
    Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373:117122.MEDLINE
  • 15
    Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996; 271:15821586.MEDLINE
  • 16
    Nowak MA, Bangham CRM. Population dynamics of immune responses to persistent viruses. Science 1996; 272:7479.MEDLINE
  • 17
    Herz AVM, Bonhoeffer S, Anderson RM, May RM, Nowak MA. Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay. Proc Natl Acad Sci U S A 1996; 93:72477251.MEDLINE
  • 18
    Bonhoeffer S, Coffin JM, Nowak MA. Human immunodeficiency virus drug therapy and virus load. J Virol 1997; 71:32753278.MEDLINE
  • 19
    Nowak MA, Lloyd A, Vasquez GM, Wiltrout TA, Wahl LM, Bischofberger N, Williams J, et al. Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J Virol 1997; 71:75187525.MEDLINE
  • 20
    Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 1996; 93:43984402.MEDLINE
  • 21
    Payne RJH, Nowak MA, Blumberg BS. The dynamics of hepatitis B virus infection. Proc Natl Acad Sci U S A 1996; 93:65426546.MEDLINE
  • 22
    Zeuzem S, de Man RA, Honkoop P, Roth WK, Schalm SW, Schmidt JM. Dynamics of hepatitis B virus infection in vivo. J Hepatol 1997; 27:431436.MEDLINE
  • 23
    Bonhoeffer S, May RM, Shaw GM, Nowak MA. Viral dynamics and drug therapy. Proc Natl Acad Sci U S A 1997; 94:69716976.MEDLINE
  • 24
    Zeuzem S, Schmidt JM, Lee J-H, Ruster B, Roth K. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996; 23:366371.MEDLINE
  • 25
    Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26:226231.MEDLINE
  • 26
    Zeuzem S, Schmidt JM, Lee J-H, von Wagner M, Teuber G, Roth WK. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology 1998; 28:245252.MEDLINE
  • 27
    Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998; 282:103107.MEDLINE
  • 28
    De Clercq E, Holy A, Rosenberg I, Sakuma T, Balzarini J, Maudgal PC. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986; 323:464467.MEDLINE
  • 29
    De Clercq E, Sakuma T, Baba M, Pauwels R, Balzarini J, Rosenberg I, Holy A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res 1987; 8:261272.MEDLINE
  • 30
    Pauwels R, Balzarini J, Schols D, Baba M, Desmyter J, Rosenberg I, Holy A, et al. Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob Agents Chemother 1988; 32:10251030.MEDLINE
  • 31
    De Clercq E. Antiviral activity spectrum and target of action of different classes of nucleoside analogues. Nucleosides Nucleotides 1994; 13:12711295.
  • 32
    Tsiang M, Dale B, Rooney J, Toole JJ, Gibbs CS. Dynamics of hepatitis B virus clearance from the serum of patients treated with adefovir dipivoxil for 12 weeks [Abstract]. Hepatology 1992; 28(Suppl 4):492A.
  • 33
    Barditch-Crovo P, Toole J, Hendrix CW, Cundy KC, Ebeling D, Jaffe HS, Lietman PS. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyl- oxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. J Infect Dis 1997; 176:406413.MEDLINE
  • 34
    Cundy KC, Sue IL, Visor GC, Marshburn J, Nakamura C, Lee WA, Shaw JP. Oral formulations of adefovir dipivoxil: in vitro dissolution and in vivo bioavailability in dogs. J Pharm Sci 1997; 86:13341338.MEDLINE
  • 35
    Orito E, Mizokami M, Ina Y, Moriyama EN, Kameshima N, Yamamoto M, Gojobori T. Host-independent evolution and a genetic classification of the hepadnavirus family based on nucleotide sequences. Proc Natl Acad Sci U S A 1989; 86:70597062.MEDLINE
  • 36
    Ni YH, Chang MH, Chen PJ, Lin HH, Hsu HY. Evolution of hepatitis C virus quasispecies in mothers and infants infected through mother-to-infant transmission. J Hepatol 1997; 26:967974.MEDLINE
  • 37
    Bianchi L, Gudat F. Viral antigens in liver tissue and type of inflammation in hepatitis B. In: BianchiL, GerokW, SickingerK, eds. Virus and the Liver. Lancaster, UK: MTP. 1980;197204.
  • 38
    Mason WS. The problem of antiviral therapy for chronic hepadnavirus infections. J Hepatol 1993; 17:S137S142.MEDLINE
  • 39
    Mason WS, Cullen J, Saputelli J, Wu TT, Liu C, London WT, Lustbader E, et al. Characterization of the antiviral effects of 2′ carbodeoxy-guanosine in ducks chronically infected with duck hepatitis B virus. Hepatology 1994; 19:398411.MEDLINE
  • 40
    Jacyna MR, Thomas HC. Pathogenesis and treatment of chronic infection. In: ZuckermanAJ, ThomasHC, eds. Viral Hepatitis. New York: Churchill Livingstone. 1993;185205.